NEKTAR THERAPEUTICS — Director's Dealing 2022

Sep 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2022-09-16

Reporting Person: Ajer Jeffrey Robert (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-16	Common Stock	A	10200	$0.00	Acquired	42710	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-16	Stock Option	$3.47	A	20400	Acquired	2030-09-15	Common Stock (20400)	Direct

Footnotes

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 16, 2022.

F3: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.